Hostname: page-component-586b7cd67f-2brh9 Total loading time: 0 Render date: 2024-11-25T10:12:14.777Z Has data issue: false hasContentIssue false
  • English
  • Français

Ideal and Reality of Neuroleptic Relapse Prevention

Published online by Cambridge University Press:  06 August 2018

Werner Kissling
Werner Kissling*
Affiliation:
Psychiatrische Klinik der Technischen Universität München, München, Germany
Get access Rights & Permissions [Opens in a new window]

Extract

The discovery of neuroleptics some 40 years ago brought about a revolution in the treatment of schizophrenia. Until then, schizophrenic patients were primarily treated with various forms of coma and shock therapy, and many were permanently confined in psychiatric hospitals. With the availability of neuroleptic medication, however, hospital stays have become considerably shorter and many patients can be returned home for out-patient care. In addition, psychosocial therapy for schizophrenic psychoses could not have been effective without the protective effect of neuroleptics.

Type
Treatment
Information
The British Journal of Psychiatry , Volume 161 , Issue S18: Onset and Course of Schizophrenic Disorders: Dynamic Interactions between Relevant Factors , October 1992 , pp. 133 - 139
Copyright
Copyright © The Royal College of Psychiatrists 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Bäuml, J., Bals, B., Schlag, K., et al (1990) Informations-zentrierte Angehörigengruppen zur Compliance-Verbesserung bei der Rezidivprophylaxe von schizophrenen Psychosen – Ergebnisse einer 1-Jahres-Katamnese. Zentralblatt für Neurologie und Psychiatrie, 255, 278.Google Scholar
Casey, D. E. (1987) Tardive dyskinesia. In Psychopharmacology. The Third Generation of Progress (ed. Meltzer, H. Y.), pp. 1411–1420. New York: Raven.Google Scholar
Chien, C. P. (1975) Drugs and rehabilitation in schizophrenia. In Drugs in Combination with other Therapies (ed. Greenblatt, M.), pp. 13–34. New York: Grune & Stratton.Google Scholar
Crow, T. J., McMillan, J. F., Johnson, A. L., et al (1986) The Northwick Park study of first episodes of schizophrenia: II. A randomised controlled trial of prophylactic neuroleptic treatment. British Journal of Psychiatry, 148, 120–127.Google Scholar
Davis, J. M. (1980) Antipsychotic drugs. In Comprehensive Textbook of Psychiatry/III (eds H. I. Kaplan, A. M. Freedman & B. J. Sadock), pp. 2257–2289. Baltimore: Williams & Wilkins.Google Scholar
Eklund, K. & Forsman, A. (1991) Minimal effective dose and relapse: double-blind trial: haldol decanoas versus placebo. Clinical Neuropharmacology, 4 (Suppl. 2), 7–15.Google Scholar
Gaebel, W. & Pietzcker, A. (1983) Indikation zur neuroleptischen Langzeitmedikation – Standardverfahren oder individual-prognostisch geleitete Intervention? Nervenarzt, 54, 467–476.Google Scholar
Gaebel, W. & Pietzcker, A. (1985) One-year-outcome of schizophrenic patients – the interaction of chronicity and neuroleptic treatment. Pharmacopsychiatry, 18, 235–239.Google Scholar
Gerlach, J. & Casey, D. E. (1988) Tardive dyskinesia. Acta Psychiatria Scandinavica, 77, 369–378.Google Scholar
Gmür, M. & Tschopp, A. (1988) Die Behandlungskontinuität bei schizophrenen Patienten in der Ambulanz. Eine Fünfjahres-nachuntersuchung. Nervenarzt, 59, 727–730.Google Scholar
Hogarty, G. E., Goldberg, S. C. & Collaborative Study Group (1974) Drug and sociotherapy in the aftercare of schizophrenic patients: one year relapse rates. Archives of General Psychiatry, 28, 54–64.Google Scholar
Hogarty, G. E., McEvoy, J. P., Munet, M., et al (1988) Dose of fluphenazine, familial expressed emotion, and outcome in schizophrenia. Archives of General Psychiatry, 45, 797–805.Google Scholar
Johnson, D. A. W. (1984) Observations on the use of long-acting depot neuroleptic injections in the maintenance therapy of schizophrenia. Journal of Clinical Psychiatry, 5, 13–21.Google Scholar
Johnson, D. A. W., Ludlow, J. M., Street, K., et al (1987) Double-blind comparison of half-dose and standard-dose flupenthixol decanoate in the maintenance treatment of stabilised out-patients with schizophrenia. British Journal of Psychiatry, 151, 634–638.Google Scholar
Kane, J. M. (1985) Compliance issues in outpatient treatment. Journal of Clinical Psychopharmacology, 5, 22–27.Google Scholar
Kane, J. M. (1987) Treatment of schizophrenia. Schizophrenia Bulletin, 13, 133–156.Google Scholar
Kane, J. M., Rifkin, A., Quitkin, F., et al (1982) Fluphenazine versus placebo in patients with remitted, acute first episode schizophrenia. Archives of General Psychiatry, 39, 70–73.Google Scholar
Kane, J. M., Rifkin, A., Woerner, M. et al (1983) Low dose neuroleptic treatment of outpatient schizophrenics. I. Preliminary results for relapse rates. Archives of General Psychiatry, 40, 893–896.Google Scholar
Kane, J. M., Woerner, M. & Lieberman, J. (1985) Tardive dyskinesia: prevalence, incidence, and risk factors. In Dyskinesia – Research and Treatment (Psychopharmacology Supplementum 2) (eds D. E. Casey, T. Chase, A. V. Christensen, et al), pp. 72–78. Berlin: Springer.Google Scholar
Kane, J. M., Woerner, M., Borenstein, M., et al (1986) Integrating incidence and prevalence of tardive dyskinesia. Psychopharmacology Bulletin, 22, 254–258.Google ScholarPubMed
Kissling, W. (ed.) (1991) Guidelines for Neuroleptic Relapse Prevention. New York: Springer.CrossRefGoogle Scholar
Kissling, W., Möller, H. J., Walter, K., et al (1985) Double-blind comparison of haloperidol decanoate and fluphenazine decanoate. Effectiveness, side-effects, dosage and serum level during a six month's treatment for relapse prevention. Pharmacopsychiatry, 3, 240–245.Google Scholar
Kissling, W., Möller, H. J., Bäuml, J., et al (1990) Fluanxol Depot 10% versus Haloperidol-Decanoat. Dosierung und Applikationsintervalle. In Thioxanthen-Kolloquium (eds B. Müller-Oerlinghausen, H. J. Möller, & E. Rüther), pp. 199–212. Berlin: Springer.Google Scholar
Leff, J. P. & Wing, J. K. (1971) Trial of maintenance therapy in schizophrenia. British Medical Journal, 3, 559–604.CrossRefGoogle ScholarPubMed
Lewandowski, L. & Buchkremer, G. (1988) Therapeutische Gruppenarbeit mit Angehörigen schizophrener Patienten. Zeitschrift für klinische Psychologie, 17, 210–224.Google Scholar
Marder, S. R., van Putten, R., Mintz, J., et al (1984) Maintenance therapy: new findings. In Drug Maintenance Strategies in Schizophenia (ed. Kane, J. M.), pp. 31–50. Washington: APA.Google Scholar
Marder, S. R., van Putten, R., Mintz, J., et al (1987) Low and conventional-dose maintenance therapy with fluphenazine decanoate. Archives of Psychiatry, 44, 518–522.Google Scholar
Marsden, C. D. (1985) Is tardive dyskinesia a unique disorder? In Dyskinesia – Research and Treatment (Psychopharmacology Suppl. 2) (eds D. E. Casey, T. Chase, A. V. Christensen, et al), pp. 64–71. Berlin: Springer.Google Scholar
Maurer, K. & Biehl, H. (1988) Klinikaufenthalte und produktive Rückfälle bei ersterkrankten Schizophrenen. Determinanten des Zeitverlaufs zwischen stationären Aufnahmen bzw. schizophrenen Rezidiven über fünf Jahre. Nervenheilkunde, 7, 279–290.Google Scholar
Müller, P. (ed.) (1982) Zur Rezidivprophylaxe schizophrener Psychosen. Stuttgart: Enke.Google Scholar
Odejide, O. A. & Aderounmu, A. F. (1982) Double-blind placebo substitution: withdrawal of fluphenazine decanoate in schizophrenic patients. Journal of Clinical Psychiatry, 43, 195–196.Google Scholar
Pietzcker, A. (1987) Neuroleptische Langzeit-Medikation in der ambulanten Behandlung schizophren Kranker. Promonta-Schriften, 8, 7–67.Google Scholar
Rifkin, A., Quitkin, F., Rabiner, C. J., et al (1977) Fluphenazine decanoate, oral fluphenazine and placebo in the treatment of remitted schizophrenics: I. Relapse rates after one year. Archives of General Psychiatry, 34, 43–47.Google Scholar
Shepherd, M., Watt, D., Falloon, I., et al (1989) The Natural History of Schizophrenia: a Five-Year Follow-up Study of Outcome and Prediction in a Representative Sample of Schizophrenics. Psychological Medicine, Monograph Suppl. 15. Cambridge: Cambridge University Press.Google Scholar
Smith, J. & Birchwood, M. (1990) Relatives and patients as partners in the management of schizophrenia. The development of a service model. British Journal of Psychiatry, 156, 654–660.Google Scholar
Trochinsky, C. H., Aaronson, H. G. & Stone, R. K. (1962) Maintenance phenothiazine in the aftercare of schizophenic patients. Pennsylvania Psychiatric Quarterly, 2, 11–15.Google Scholar
Wistedt, B. (1981) A depot neuroleptic withdrawal study: a controlled study of the clinical effects of the withdrawal of depot fluphenazine decanoate and depot flupenthixol decanoate in chronic schizophrenic patients. Acta Psychiatrica Scandinavica, 64, 65–84.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.